DSP 6952

Drug Profile

DSP 6952

Alternative Names: DSP-6952

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sumitomo Dainippon Pharma
  • Class Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation; Irritable bowel syndrome

Most Recent Events

  • 31 Jan 2017 Phase-II clinical trials in Constipation in Japan (PO) before January 2017 (Sumitomo Dainippon Pharma pipline, January 2017)
  • 01 Nov 2016 Dainippon Sumitomo Pharma initiates a phase II trial for Irritable bowel syndrome (in patients with constipation) in Japan (PO) (JapicCTI163459)
  • 14 Jan 2016 Phase II development is ongoing for Constipation and Irritable bowed syndrome with constipation in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top